A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Not Yet Recruiting. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 2
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · DOUBLE
- Evidence population
- Human clinical study registration
- Participants
- 321
- Population
- ALL · 50 Years
- Duration
- 2026-09-30 to 2030-08-21
- Intervention
- RO7965032; Placebo
- Comparator
- Placebo
- Outcomes measured
- Change of GA Lesion Area in the Study Eye — Baseline up to approximately 48 weeks; Incidence and Severity of Ocular Adverse Events (AEs) — Up to approximately 72 Weeks; Incidence and Severity of Non-Ocular AEs — Up to approximately 72 Weeks; Change of GA Lesion Area in the Study Eye — Baseline up to approximately 72 weeks; Change from Baseline in Best Correct Visual Acuity (BCVA) Score on the Early Treatment Diabetic Retinopathy Study (ETDR…; Change from Baseline in BCVA Score on the ETDRS Chart Under Low-luminance Conditions — Baseline up to approximately 48…; Incidence and Severity of Selected Findings in Ocular Examinations and Ocular Imaging — Up to approximately 72 Weeks; Plasma Concentration of RO7965032 — Baseline up to approximately 72 weeks; Percent Change from Baseline in Levels of Target Protein in Plasma — Baseline up to approximately 72 weeks; Percent Change from Baseline in Levels of Plasma Biomarker Activity — Baseline up to approximately 72 weeks; Prevalence and Incidence of Anti-Drug Antibodies (ADAs) — Baseline up to approximately 72 weeks; Recommended Dose of RO7965032 — Up to approximately 72 Weeks
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Source terminology contains a controlled topic term. Title supplies ageing or longevity context.
Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.